Enhancements include symptom correlation to ECG readings
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today confirms it has released a new version of its GEMS Home software which is available to both new purchasers of the HeartCheckTM PEN ECG device as well as a free upgrade to current HeartCheckTM PEN owners.
CardioComm Solutions has long history of licensing its Global ECG Management System software to hospitals and medical call centres. The new GEMS Home release incorporates additional SMART Monitoring features that are similar to those seen with mobile/ambulatory cardiac monitoring (MCT) solutions. Consumers may now provide symptoms and activity entries, in addition to making free text notes and confirming whether they have pre-existing medical conditions. "The interpretation of the ECG rhythm strip is enhanced by knowledge of levels of activity at which it was recorded. Correlation with symptoms provides clinical relevance and diagnostic accuracy. This improvement in GEMS Home recording and reporting capability will be appreciated by the users of the HeartCheckTM service," said Dr. Anatoly Langer, Chairman of the Company Board of Directors and Professor of Medicine, University of Toronto.
Launched in 2012, the HeartCheckTM PEN ECG device and associated GEMS Home software, remains the only FDA and Health Canada cleared, over-the-counter (OTC) medical monitoring device in North America that is permitted to show a person their own heart electrocardiogram (ECG) without a physician prescription. GEMS Home enables heart rhythm recordings to be moved from the HeartCheckTM PEN to a computer for review. GEMS Home is also the gateway to the Company's patent-pending SMART Monitoring service which is central to consumers unlocking the HeartCheckTM PEN and seeing their ECG while recording, in playback or within GEMS Home. With SMART Monitoring, GEMS Home enables the consumer to select whether to send their ECG readings to a physician, or ECG technologist, for interpretation and to receive back an ECG interpretation report an average time of 30 minutes.
"Customers have reported they use the HeartCheckTM PEN and SMART Monitoring service to confirm potential arrhythmias that they have been experiencing and which were missed during prior physician prescribed monitoring attempts. This GEMS Home release provides context which is important for each interpretation that is made. The changes were prompted by both physician reviews of our products as well as user feedback," said Etienne Grima, Chief Executive Officer of the Company. "As we look to introducing new monitoring devices to our SMART Monitoring service, and work towards multi-language releases of GEMS Home, we will continue to provide new updates to our customers and distributors."
More information regarding the HeartCheckTM products and SMART monitoring solutions is available at the Company's web site www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.